Satsuma Pharmaceuticals (NASDAQ:STSA – Get Rating) had its price target increased by HC Wainwright from $15.00 to $18.00 in a research report report published on Wednesday, The Fly reports. HC Wainwright currently has a buy rating on the financial services provider’s stock.
Several other analysts have also recently issued reports on STSA. Mizuho reissued a buy rating and set a $13.00 price target on shares of Satsuma Pharmaceuticals in a research report on Wednesday, June 1st. Jonestrading began coverage on shares of Satsuma Pharmaceuticals in a research report on Wednesday, August 24th. They set a buy rating and a $14.00 price target on the stock. Finally, LADENBURG THALM/SH SH began coverage on shares of Satsuma Pharmaceuticals in a research report on Wednesday, August 31st. They set a buy rating and a $16.00 price target on the stock. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat, Satsuma Pharmaceuticals has an average rating of Moderate Buy and an average target price of $13.20.
Satsuma Pharmaceuticals Price Performance
Shares of STSA stock opened at $7.90 on Wednesday. The firm has a market cap of $249.54 million, a PE ratio of -4.11 and a beta of 0.50. Satsuma Pharmaceuticals has a 1-year low of $2.51 and a 1-year high of $7.98. The company has a 50-day moving average of $5.73 and a two-hundred day moving average of $4.41.
Institutional Trading of Satsuma Pharmaceuticals
About Satsuma Pharmaceuticals
Satsuma Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. The company's lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in SUMMIT Phase 3 efficacy trials and can be self-administered with proprietary pre-filled, single-use, and nasal delivery device.
- Get a free copy of the StockNews.com research report on Satsuma Pharmaceuticals (STSA)
- The Worst May be Over for Target, But is the Stock Safe to Buy?
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- Two Fun Stocks The Insiders Are Buying
- Novavax Remains a Risk-On Stock in a Risk-Off Market
- General Mills: Superior Returns With Less Volatility
Receive News & Ratings for Satsuma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Satsuma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.